TREATMENT OF THE TYPE 2 OF DIABETES PATIENTS WITH THE SECONDARY FAILURE OF THE ORAL THERAPY: COMPARISON OF THE INSULIN-SULFONYLUREA REGIME AND THAT OF THE INSULIN-METFORMIN

The regime of combined therapies, namely, insulin plus an oral anti diabetics, represents a rational alternative to the monoinsulin therapy, especially in the group of moderately obese patients with the signs of the secondary failure of the oral therapy. There has been the insulin-sulfonylurea therapy applied for many years; however, reemergence of metformin in the diabetological practice in the last few years has conditioned an increase of interest in the insulin-metformin combination. The research has comprised 37 of the type 2 diabetes patients who were, after the secondary failure of the oral therapy was determined, subjected to various regimes of the combined therapy with the purpose of comparing the efficiency of the two regimes, namely, of the insulin-sulfonylurea and the insulin-metformin ones. The results clearly show the advantages of the insulin-metformin regime. They primarily refer to the possibility of achieving the same level of glycoregulation with smaller insulin doses. The insulin-metformin combination causes a considerably better insulin prandial profile while it shows smaller advantages regarding the correction of lipid abnormalities in the examined patients.